Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Therapeutic product effect delayed? 178 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 178 reports of Therapeutic product effect delayed have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.1% of all adverse event reports for TOFACITINIB.

178
Reports of Therapeutic product effect delayed with TOFACITINIB
0.1%
of all TOFACITINIB reports
7
Deaths
20
Hospitalizations

How Dangerous Is Therapeutic product effect delayed From TOFACITINIB?

Of the 178 reports, 7 (3.9%) resulted in death, 20 (11.2%) required hospitalization, and 2 (1.1%) were considered life-threatening.

Is Therapeutic product effect delayed Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 178 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Therapeutic product effect delayed?

ADALIMUMAB (244) CARBIDOPA\LEVODOPA (168) SECUKINUMAB (162) POLYETHYLENE GLYCOL 3350 (125) RIMEGEPANT (120) TASIMELTEON (93) DUPILUMAB (90) IBUPROFEN (88) DICLOFENAC (85) ERENUMAB-AOOE (82)

Which TOFACITINIB Alternatives Have Lower Therapeutic product effect delayed Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Therapeutic product effect delayed Reports All Drugs Causing Therapeutic product effect delayed TOFACITINIB Demographics